This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Steven P. Schulman, MD

JAMA. 2004;292:1875-1882.

ABSTRACT
Acute coronary syndromes are a frequent cause of hospital admission for patients with coronary artery disease. The pathophysiology of acute coronary syndromes often involves plaque rupture or fissure with platelet aggregation. Recognition of the importance of platelet aggregation resulted in several large randomized trials testing 3 types of platelet antagonists, aspirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors. A thorough understanding of the data, risks, and benefits of these therapies is important to optimize treatment of the patient with an acute coronary syndrome. Recognition that there is a great deal of interpatient variability in response to these antiplatelet therapies highlights the need for future research in this area.

Author Affiliation: Coronary Care Unit, The Johns Hopkins Hospital, Baltimore, Md.

Corresponding Author: Steven P. Schulman, MD, Coronary Care Unit, The Johns Hopkins Hospital, 601 N Wolfe St, Carnegie 568, Baltimore, MD 21287 (sschulm{at}jhmi.edu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
Hagihara et al.
Drug Metab. Dispos. 2009;37:2145-2152.
ABSTRACT | FULL TEXT  

New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Van de Werf
Eur Heart J 2009;30:1695-1702.
ABSTRACT | FULL TEXT  

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
Ndrepepa et al.
Eur Heart J 2008;29:455-461.
ABSTRACT | FULL TEXT  

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
Hernandez et al.
Heart 2007;93:450-455.
ABSTRACT | FULL TEXT  

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Kastrati et al.
JAMA 2006;295:1531-1538.
ABSTRACT | FULL TEXT  

Electrocardiographic Findings in Non-ST-Segment Elevation Myocardial Infarction
Schlegel
JAMA 2005;293:423-423.
FULL TEXT